

Benjamin M Greenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3397191/publications.pdf>

Version: 2024-02-01

171
papers

9,721
citations

66343

42
h-index

39675

94
g-index

178
all docs

178
docs citations

178
times ranked

8740
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.1	3,275
2	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2114-2124.	27.0	383
3	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 402-412.	10.2	278
4	Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2014, 71, 324.	9.0	258
5	Epidemiology of Neuromyelitis Optica in the United States. <i>Archives of Neurology</i> , 2012, 69, 1176-80.	4.5	239
6	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 1017-1027.	27.0	237
7	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	3.0	209
8	Transverse Myelitis. <i>Neurologic Clinics</i> , 2013, 31, 79-138.	1.8	172
9	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017, 88, 1623-1629.	1.1	138
10	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.1	129
11	Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2018, 90, e1815-e1821.	1.1	123
12	Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4 ⁺ cell proliferation and IFN- γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. <i>European Journal of Immunology</i> , 2010, 40, 2942-2956.	2.9	114
13	Current and emerging therapies in multiple sclerosis: a systematic review. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 205-220.	3.5	112
14	Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. <i>Journal of the Neurological Sciences</i> , 2009, 282, 96-105.	0.6	110
15	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	10.2	110
16	Natalizumab and Progressive Multifocal Leukoencephalopathy. <i>Archives of Neurology</i> , 2010, 67, 923-30.	4.5	105
17	Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1022-1026.	3.0	105
18	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	6.0	104

#	ARTICLE	IF	CITATIONS
19	In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. <i>Circulation</i> , 2021, 144, 487-498.	1.6	102
20	Pediatric transverse myelitis. <i>Neurology</i> , 2016, 87, S46-52.	1.1	92
21	Acute flaccid myelitis: cause, diagnosis, and management. <i>Lancet, The</i> , 2021, 397, 334-346.	13.7	88
22	Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1044-51.	4.5	78
23	Elevated CNS Inflammation in Patients with Preclinical Alzheimer's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 30-33.	4.3	74
24	The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 1421.	9.0	73
25	A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. <i>Nature Communications</i> , 2018, 9, 1929.	12.8	73
26	Uhthoff's phenomena in MS—clinical features and pathophysiology. <i>Nature Reviews Neurology</i> , 2013, 9, 535-540.	10.1	70
27	Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. <i>Journal of Autoimmunity</i> , 2011, 36, 115-124.	6.5	68
28	Herpes Simplex Encephalitis as a Potential Cause of Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis. <i>JAMA Neurology</i> , 2014, 71, 344.	9.0	68
29	Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. <i>Clinical and Experimental Immunology</i> , 2014, 175, 397-407.	2.6	68
30	Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-d-aspartate receptor antibody encephalitis: A retrospective review. <i>Journal of Clinical Apheresis</i> , 2015, 30, 212-216.	1.3	68
31	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 897-907.	3.7	67
32	JC Virus in CD34 ⁺ and CD19 ⁺ Cells in Patients With Multiple Sclerosis Treated With Natalizumab. <i>JAMA Neurology</i> , 2014, 71, 596.	9.0	65
33	Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 735-740.	3.0	61
34	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
35	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1350-1353.	1.9	58
36	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 87-92.	2.0	58

#	ARTICLE	IF	CITATIONS
37	Statistical classifiers for diagnosing disease from immune repertoires: a case study using multiple sclerosis. <i>BMC Bioinformatics</i> , 2017, 18, 401.	2.6	57
38	Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity. <i>Autoimmunity</i> , 2012, 45, 400-414.	2.6	52
39	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019, 15, e1007808.	3.5	48
40	Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 30-33.	2.0	48
41	Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. <i>Clinical Immunology</i> , 2014, 152, 115-126.	3.2	46
42	The spectrum of autoimmune encephalopathies. <i>Journal of Neuroimmunology</i> , 2015, 287, 93-97.	2.3	46
43	CD40-Mediated NF- κ B Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. <i>Journal of Immunology</i> , 2016, 197, 4257-4265.	0.8	45
44	Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. <i>PLoS Pathogens</i> , 2012, 8, e1003014.	4.7	44
45	Home-Based Pediatric Teleneuropsychology: A validation study. <i>Archives of Clinical Neuropsychology</i> , 2020, 35, 1266-1275.	0.5	43
46	Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 86-90.	2.0	42
47	Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 326-334.	2.0	41
48	Three Phenotypes of Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis in Children: Prevalence of Symptoms and Prognosis. <i>Pediatric Neurology</i> , 2014, 51, 542-549.	2.1	41
49	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1737-1742.	3.0	41
50	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018, 14, 433-445.	10.1	41
51	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.1	39
52	Bacteraemia in the elderly: predictors of outcome in an urban teaching hospital. <i>Journal of Infection</i> , 2005, 50, 288-295.	3.3	38
53	Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis. <i>Child Neuropsychology</i> , 2014, 20, 71-85.	1.3	38
54	Optical coherence tomography as a potential readout in clinical trials. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 153-160.	3.5	37

#	ARTICLE	IF	CITATIONS
55	Genetic risk factors for pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1825-1834.	3.0	37
56	<i>BRAF</i> mutation leading to central nervous system rosai-Erdorfman disease. <i>Annals of Neurology</i> , 2018, 84, 147-152.	5.3	37
57	The Neurologic Manifestations of Systemic Lupus Erythematosus. <i>Neurologist</i> , 2009, 15, 115-121.	0.7	35
58	Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. <i>Neurology</i> , 2013, 80, 1862-1866.	1.1	35
59	No Cerebral or Cervical Venous Insufficiency in US Veterans With Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1521.	4.5	33
60	Symptomatic therapy in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 83-98.	3.5	33
61	Optic neuritis: A mechanistic view. <i>Pathophysiology</i> , 2011, 18, 81-92.	2.2	32
62	Transverse Myelitis Plus Syndrome and Acute Disseminated Encephalomyelitis Plus Syndrome. <i>JAMA Neurology</i> , 2014, 71, 624.	9.0	30
63	Peripheral VH4+Âplasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. <i>Acta Neuropathologica</i> , 2017, 133, 43-60.	7.7	30
64	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 15-28.	3.5	29
65	Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 937-949.	2.8	29
66	Urban air quality and associations with pediatric multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1146-1153.	3.7	29
67	Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. <i>Journal of Pharmacy Practice</i> , 2018, 31, 481-488.	1.0	28
68	Dietary factors and pediatric multiple sclerosis: A case-control study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1067-1076.	3.0	27
69	Analysis of 30 Spinal Angiograms Falsely Reported as Normal in 18 Patients with Subsequently Documented Spinal Vascular Malformations. <i>American Journal of Neuroradiology</i> , 2017, 38, 1814-1819.	2.4	26
70	Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model. <i>Journal of Autoimmunity</i> , 2018, 86, 104-115.	6.5	26
71	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 483-492.	1.9	26
72	COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	26

#	ARTICLE	IF	CITATIONS
73	A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHlgM22 in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731774309.	1.0	25
74	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1222-1228.	3.7	25
75	INFECTIOUS COMPLICATIONS OF TEMPORARY SPINAL CATHETER INSERTION FOR DIAGNOSIS OF ADULT HYDROCEPHALUS AND IDIOPATHIC INTRACRANIAL HYPERTENSION. <i>Neurosurgery</i> , 2008, 62, 431-436.	1.1	23
76	Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. <i>Neurology</i> , 2012, 79, 797-801.	1.1	23
77	Top-Down Mass Spectrometry on Tissue Extracts and Biofluids with Isoelectric Focusing and Superficially Porous Silica Liquid Chromatography. <i>Analytical Chemistry</i> , 2013, 85, 10377-10384.	6.5	23
78	Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases. <i>Pediatric Neurology</i> , 2018, 86, 42-45.	2.1	22
79	Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease. <i>Archives of Neurology</i> , 2012, 69, 352.	4.5	21
80	Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. <i>Clinical Immunology</i> , 2013, 147, 105-119.	3.2	21
81	Examining the contributions of environmental quality to pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 164-169.	2.0	21
82	Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease. <i>Molecular Therapy</i> , 2021, 29, 1312-1323.	8.2	20
83	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2025-2037.	3.7	20
84	Direct and consensual murine pupillary reflex metrics: Establishing normative values. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2009, 151, 164-167.	2.8	19
85	Urodynamics findings in transverse myelitis patients with lower urinary tract symptoms: Results from a tertiary referral urodynamic center. <i>Neurourology and Urodynamics</i> , 2017, 36, 360-363.	1.5	19
86	A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients. <i>ASN Neuro</i> , 2015, 7, 175909141560961.	2.7	18
87	Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 211-215.	3.5	18
88	MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. <i>Gene</i> , 2015, 572, 191-197.	2.2	17
89	Safety and efficacy of plasma exchange in pediatric transverse myelitis. <i>Neurology: Clinical Practice</i> , 2018, 8, 327-330.	1.6	17
90	Vitamin D genes influence MS relapses in children. <i>Multiple Sclerosis Journal</i> , 2020, 26, 894-901.	3.0	17

#	ARTICLE	IF	CITATIONS
91	Human Aquaporin 4₂₈₁₋₃₀₀ Is the Immunodominant Linear Determinant in the Context of HLA-DRB1*03:01. Archives of Neurology, 2012, 69, 1125-31.	4.5	16
92	A Surprisingly Low Prevalence of Demonstrable Stress Urinary Incontinence and Pelvic Organ Prolapse in Women with Multiple Sclerosis Followed at a Tertiary Neurogenic Bladder Clinic. Journal of Urology, 2013, 189, 976-979.	0.4	16
93	High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes. Journal of the Neurological Sciences, 2017, 372, 187-195.	0.6	16
94	Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
95	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. Multiple Sclerosis and Related Disorders, 2022, 66, 104025.	2.0	15
96	“Light Switch” Mental Status Changes and Irritable Insomnia are Two Particularly Salient Features of Anti-NMDA Receptor Antibody Encephalitis. Pediatric Neurology, 2014, 51, 151-153.	2.1	14
97	Pediatric Multiple Sclerosis. Neurologic Clinics, 2018, 36, 135-149.	1.8	14
98	Acute Disseminated Encephalomyelitis (ADEM) and Increased Intracranial Pressure Associated With Anti-“Myelin Oligodendrocyte Glycoprotein Antibodies. Pediatric Neurology, 2019, 99, 64-68.	2.1	14
99	Future Research Directions in Multiple Sclerosis Therapies. Seminars in Neurology, 2008, 28, 121-127.	1.4	13
100	Objective characterization of the relative afferent pupillary defect in MS. Journal of the Neurological Sciences, 2012, 323, 193-200.	0.6	13
101	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248.	9.0	13
102	Central Nervous System Infections in the Intensive Care Unit. Seminars in Neurology, 2008, 28, 682-689.	1.4	12
103	Neuromyelitis Optica Spectrum Disorder Associated With Autoimmune Hemolytic Anemia and Lymphoma. Neurologist, 2015, 20, 33-34.	0.7	12
104	Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. Children, 2019, 6, 70.	1.5	12
105	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
106	Translational Research in Neurology and Neuroscience 2010. Archives of Neurology, 2010, 67, 1307-15.	4.5	11
107	CSF-Derived CD4+ T-Cell Diversity Is Reduced in Patients With Alzheimer Clinical Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1106.	6.0	11
108	Cryptococcal Meningitis Reported With Fingolimod Treatment. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	11

#	ARTICLE	IF	CITATIONS
109	Treatment of Acute Transverse Myelitis and Its Early Complications. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 733-743.	0.8	10
110	Expansion of CD27 ^{high} plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes and Immunity, 2013, 14, 291-301.	4.1	10
111	The Antibody Genetics of Multiple Sclerosis: Comparing Next-Generation Sequencing to Sanger Sequencing. Frontiers in Neurology, 2014, 5, 166.	2.4	10
112	Equivalent Gene Expression Profiles between Glatopa [®] and Copaxone [®] . PLoS ONE, 2015, 10, e0140299.	2.5	10
113	mi RNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	3.7	10
114	Proteofom analysis of lipocalin-type prostaglandin synthase from human cerebrospinal fluid by isoelectric focusing and superficially porous liquid chromatography with Fourier transform mass spectrometry. Proteomics, 2014, 14, 1223-1231.	2.2	9
115	Vitamin D During Pregnancy and Multiple Sclerosis. JAMA Neurology, 2016, 73, 498.	9.0	9
116	Cognitive functioning in pediatric transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 947-952.	3.0	8
117	Neuropsychological outcomes of pediatric demyelinating diseases: a review. Child Neuropsychology, 2018, 24, 575-597.	1.3	8
118	Several household chemical exposures are associated with pediatric-onset multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1513-1521.	3.7	8
119	Assessment of Renal Deterioration and Associated Risk Factors in Patients With Multiple Sclerosis. Urology, 2019, 123, 76-80.	1.0	8
120	Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma. Journal of Neuroimmunology, 2020, 338, 577092.	2.3	8
121	Clinical Features, Treatment Strategies, and Outcomes in Hospitalized Children With Immune-Mediated Encephalopathies. Pediatric Neurology, 2021, 116, 20-26.	2.1	8
122	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. Multiple Sclerosis Journal, 2022, 28, 1330-1339.	3.0	8
123	Neurotherapeutic Strategies for Multiple Sclerosis. Neurologic Clinics, 2016, 34, 483-523.	1.8	7
124	New onset transverse myelitis diagnostic accuracy and patient experiences. Multiple Sclerosis and Related Disorders, 2019, 30, 42-44.	2.0	7
125	A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR. PLoS ONE, 2016, 11, e0152720.	2.5	7
126	CURRENT AND EMERGING MULTIPLE SCLEROSIS THERAPEUTICS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 58-77.	0.8	6

#	ARTICLE	IF	CITATIONS
127	Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 337-338.	10.2	6
128	Interferon Beta and Long-term Disability in Multiple Sclerosis—Reply. <i>JAMA Neurology</i> , 2013, 70, 651.	9.0	6
129	Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis. <i>Clinical Immunology</i> , 2016, 166-167, 12-18.	3.2	6
130	Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitis. <i>BMJ Neurology Open</i> , 2021, 3, e000127.	1.6	6
131	<scp>Aptamer-Based</scp> Screen of Neuropsychiatric Lupus Cerebrospinal Fluid Reveals Potential Biomarkers That Overlap With the Choroid Plexus Transcriptome. <i>Arthritis and Rheumatology</i> , 2022, 74, 1223-1234.	5.6	6
132	Immune-Mediated Myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 121-131.	0.8	5
133	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. <i>Journal of the Neurological Sciences</i> , 2017, 375, 371-375.	0.6	5
134	Persistence of parenchymal and perivascular T-cells in treatment-refractory anti-N-methyl-D-aspartate receptor encephalitis. <i>NeuroReport</i> , 2017, 28, 890-895.	1.2	5
135	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019, 34, 148-152.	1.4	5
136	Revisiting Transverse Myelitis: Moving Toward a New Nomenclature. <i>Frontiers in Neurology</i> , 2020, 11, 519468.	2.4	5
137	Heterozygous Cystic Fibrosis Transmembrane Regulator Gene Missense Variants Are Associated With Worse Cardiac Function in Patients With Duchenne Muscular Dystrophy. <i>Journal of the American Heart Association</i> , 2020, 9, e016799.	3.7	5
138	Limitations of cell-lineage-specific non-dynamic gene recombination in CD11c.Cre+ITGA4fl/fl mice. <i>Journal of Neuroimmunology</i> , 2020, 344, 577245.	2.3	5
139	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 922-932.	3.0	5
140	Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States. <i>International Journal of MS Care</i> , 2021, 23, 101-105.	1.0	5
141	Interocular Difference in Retinal Nerve Fiber Layer Thickness Predicts Optic Neuritis in Pediatric-Onset Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 469-475.	0.8	5
142	Pearls: Multiple Sclerosis. <i>Seminars in Neurology</i> , 2010, 30, 097-101.	1.4	4
143	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	4
144	Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma. <i>Multiple Sclerosis Journal</i> , 2022, 28, 160-163.	3.0	4

#	ARTICLE	IF	CITATIONS
145	Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder" Neurology and Therapy, 2022, 11, 1439-1443.	3.2	4
146	Placebo studies should not be undertaken in NMO "No. Multiple Sclerosis Journal, 2015, 21, 691-693.	3.0	3
147	Neurological infections in 2020: COVID-19 takes centre stage. Lancet Neurology, The, 2021, 20, 17-18.	10.2	3
148	Carotid Cavernous Fistula Imitating Brainstem Glioma. Archives of Neurology, 2011, 68, 256-7.	4.5	2
149	What Is the True Clinicopathologic Spectrum of Neuromyelitis Optica?"Reply. JAMA Neurology, 2013, 70, 272.	9.0	2
150	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 22, 103-107.	2.0	2
151	A Callosal Catastrophe: Toxic Leukoencephalopathy Associated with Thermogenic Weight Loss Supplement Use. Neurocritical Care, 2018, 29, 504-507.	2.4	2
152	The princess and the <i>p</i> -value: A case report of suspected autoimmune encephalitis and functional neurological disorder in a pediatric patient. Applied Neuropsychology: Child, 2020, 9, 13-20.	1.4	2
153	Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate. Current Medical Research and Opinion, 2020, 36, 1167-1175.	1.9	2
154	Bladder management in children with transverse myelitis. Journal of Pediatric Urology, 2021, 17, 522.e1-522.e6.	1.1	2
155	Reconstituting T cell receptor selection in-silico. Genes and Immunity, 2021, 22, 187-193.	4.1	2
156	Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1079.	6.0	2
157	Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus. Journal of the Neurological Sciences, 2021, 430, 118053.	0.6	2
158	Determining Prevalence of Depression and Covariates of Depression in a Cohort of Multiple Sclerosis Patients. Journal of Central Nervous System Disease, 2022, 14, 117957352210981.	1.9	2
159	A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHlgM22 in subjects with multiple sclerosis immediately following a relapse. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210914.	1.0	2
160	Retroperitoneal approach for the treatment of diaphragmatic crus syndrome: technical note. Journal of Neurosurgery: Spine, 2020, 33, 114-119.	1.7	1
161	Clinical cases in neurology from Johns Hopkins. Case 2: acute ascending paralysis in a 4-year-old boy. MedGenMed: Medscape General Medicine, 2003, 5, 36.	0.2	1
162	Predicting the Outcome of Shunt Surgery in Normal Pressure Hydrocephalus. Neurosurgery, 2010, 66, E1217.	1.1	0

#	ARTICLE	IF	CITATIONS
163	Corrigendum. <i>Clinical Neuropsychologist</i> , 2010, 24, 1092-1092.	2.3	0
164	Blind and Confused. <i>JAMA Neurology</i> , 2013, 70, 932.	9.0	0
165	Peripheral Nerve Involvement in Adult and Pediatric Patients With Central Nervous System Inflammatory Disease—Reply. <i>JAMA Neurology</i> , 2015, 72, 123.	9.0	0
166	What is causing this patient's headache and seizures?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018, 31, 56-57.	0.3	0
167	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2019, 92, 151.2-151.	1.1	0
168	Clinical Approach to Autoimmune Myelitis and Myelopathy. , 2021, , 433-445.		0
169	Physician Compensation in the United States — Through the Lens of the MS Neurologist. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102847.	2.0	0
170	Acute Disseminated Encephalomyelitis. , 2017, , .		0
171	Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures. <i>Annals of Clinical Case Reports</i> , 2016, 1, .	0.6	0